Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (351-360 of 560) with videos related to

Pageof 56
Sort By:
The Biochemical Journal|November 4, 2000
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinaseX Fang, S Yu, R LaPushin, et al.
Gynecologic Oncology|December 22, 2007
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007Alan Ashworth, Frances Balkwill, Robert C Bast, et al.
Frontiers in Oncology|February 20, 2018
Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer CellsYanfang Li, Tao Liu, Cristina Ivan, et al.
Cancer Research|June 11, 1991
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cellsK R Jerome, D L Barnd, K M Bendt, et al.
Cancer Research|January 25, 1991
Coexpression of different antigenic markers on moieties that bear CA 125 determinantsY H Yu, D M Schlossman, C L Harrison, et al.
Journal of Experimental Therapeutics & Oncology|January 29, 2013
A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesisEdmond J Auzenne, Jim Klostergaard, Pijus K Mandal, et al.
Gynecologic Oncology|May 23, 2008
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusRichard G Moore, Amy K Brown, M Craig Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancerW P Peters, M Ross, J J Vredenburgh, et al.
Cancer Research|April 15, 1989
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potentialA Berchuck, A P Soisson, D L Clarke-Pearson, et al.
Gynecologic Oncology|March 30, 1999
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic massesZ Zhang, S D Barnhill, H Zhang, et al.
Pageof 56

Showing results (351-360 of 560) with videos related to

Sort By:
Pageof 56
The Biochemical Journal|November 4, 2000
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinaseX Fang, S Yu, R LaPushin, et al.
Gynecologic Oncology|December 22, 2007
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007Alan Ashworth, Frances Balkwill, Robert C Bast, et al.
Frontiers in Oncology|February 20, 2018
Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer CellsYanfang Li, Tao Liu, Cristina Ivan, et al.
Cancer Research|June 11, 1991
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cellsK R Jerome, D L Barnd, K M Bendt, et al.
Cancer Research|January 25, 1991
Coexpression of different antigenic markers on moieties that bear CA 125 determinantsY H Yu, D M Schlossman, C L Harrison, et al.
Journal of Experimental Therapeutics & Oncology|January 29, 2013
A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesisEdmond J Auzenne, Jim Klostergaard, Pijus K Mandal, et al.
Gynecologic Oncology|May 23, 2008
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusRichard G Moore, Amy K Brown, M Craig Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancerW P Peters, M Ross, J J Vredenburgh, et al.
Cancer Research|April 15, 1989
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potentialA Berchuck, A P Soisson, D L Clarke-Pearson, et al.
Gynecologic Oncology|March 30, 1999
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic massesZ Zhang, S D Barnhill, H Zhang, et al.
Pageof 56